These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 35670354)

  • 1. Phytochemicals and Nanoparticles in the Modulation of PI3K/Akt/mTOR Kinases and its Implications in the Development and Progression of Gastrointestinal Cancers: A Review of Preclinical and Clinical Evidence.
    Narayanankutty A; Nambiattil S; Mannarakkal S
    Recent Pat Anticancer Drug Discov; 2023; 18(3):307-324. PubMed ID: 35670354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitory Potential of Dietary Nutraceuticals on Cellular PI3K/Akt Signaling: Implications in Cancer Prevention and Therapy.
    Narayanankutty A
    Curr Top Med Chem; 2021; 21(20):1816-1831. PubMed ID: 34279200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PI3K/ Akt/ mTOR Pathway as a Therapeutic Target for Colorectal Cancer: A Review of Preclinical and Clinical Evidence.
    Narayanankutty A
    Curr Drug Targets; 2019; 20(12):1217-1226. PubMed ID: 31215384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phytochemicals as PI3K/ Akt/ mTOR Inhibitors and Their Role in Breast Cancer Treatment.
    Narayanankutty A
    Recent Pat Anticancer Drug Discov; 2020; 15(3):188-199. PubMed ID: 32914720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natural Products as PI3K/ Akt Inhibitors: Implications in Preventing Hepatocellular Carcinoma.
    Narayanankutty A
    Curr Mol Pharmacol; 2021; 14(5):760-769. PubMed ID: 33494690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The PI3K/Akt/mTOR axis in colorectal cancer: Oncogenic alterations, non-coding RNAs, therapeutic opportunities, and the emerging role of nanoparticles.
    Sanaei MJ; Baghery Saghchy Khorasani A; Pourbagheri-Sigaroodi A; Shahrokh S; Zali MR; Bashash D
    J Cell Physiol; 2022 Mar; 237(3):1720-1752. PubMed ID: 34897682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated PDK1 Expression Drives PI3K/AKT/MTOR Signaling Promotes Radiation-Resistant and Dedifferentiated Phenotype of Hepatocellular Carcinoma.
    Bamodu OA; Chang HL; Ong JR; Lee WH; Yeh CT; Tsai JT
    Cells; 2020 Mar; 9(3):. PubMed ID: 32197467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long Non-Coding RNA XLOC_006753 Promotes the Development of Multidrug Resistance in Gastric Cancer Cells Through the PI3K/AKT/mTOR Signaling Pathway.
    Zeng L; Liao Q; Zou Z; Wen Y; Wang J; Liu C; He Q; Weng N; Zeng J; Tang H; Fang R; Lei Z; Tang Z; Yang X; Cui S
    Cell Physiol Biochem; 2018; 51(3):1221-1236. PubMed ID: 30481766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natural products targeting the PI3K-Akt-mTOR signaling pathway in cancer: A novel therapeutic strategy.
    Tewari D; Patni P; Bishayee A; Sah AN; Bishayee A
    Semin Cancer Biol; 2022 May; 80():1-17. PubMed ID: 31866476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FOXD1-AS1 regulates FOXD1 translation and promotes gastric cancer progression and chemoresistance by activating the PI3K/AKT/mTOR pathway.
    Wu Q; Ma J; Wei J; Meng W; Wang Y; Shi M
    Mol Oncol; 2021 Jan; 15(1):299-316. PubMed ID: 32460412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of disease: PI3K/AKT signaling in gastrointestinal cancers.
    Michl P; Downward J
    Z Gastroenterol; 2005 Oct; 43(10):1133-9. PubMed ID: 16220453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. To Investigate the Occurrence and Development of Colorectal Cancer Based on the PI3K/AKT/mTOR Signaling Pathway.
    Zhong J; Ding S; Zhang X; Di W; Wang X; Zhang H; Chen Y; Zhang Y; Hu Y
    Front Biosci (Landmark Ed); 2023 Feb; 28(2):37. PubMed ID: 36866550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer.
    Yu L; Wei J; Liu P
    Semin Cancer Biol; 2022 Oct; 85():69-94. PubMed ID: 34175443
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Qian Y; Yan Y; Lu H; Zhou T; Lv M; Fang C; Hou J; Li W; Chen X; Sun H; Li Y; Wang Z; Zhao N; Gu Y; Ding Y; Liu Y
    Anticancer Agents Med Chem; 2019; 19(14):1754-1761. PubMed ID: 31364518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of regulatory miRNAs of the PI3K/AKT/mTOR signaling in the pathogenesis of hepatocellular carcinoma.
    Rahmani F; Ziaeemehr A; Shahidsales S; Gharib M; Khazaei M; Ferns GA; Ryzhikov M; Avan A; Hassanian SM
    J Cell Physiol; 2020 May; 235(5):4146-4152. PubMed ID: 31663122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway.
    Chen D; Lin X; Zhang C; Liu Z; Chen Z; Li Z; Wang J; Li B; Hu Y; Dong B; Shen L; Ji J; Gao J; Zhang X
    Cell Death Dis; 2018 Jan; 9(2):123. PubMed ID: 29374144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway.
    Burris HA
    Cancer Chemother Pharmacol; 2013 Apr; 71(4):829-42. PubMed ID: 23377372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance.
    Ediriweera MK; Tennekoon KH; Samarakoon SR
    Semin Cancer Biol; 2019 Dec; 59():147-160. PubMed ID: 31128298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How can we turn the PI3K/AKT/mTOR pathway down? Insights into inhibition and treatment of cancer.
    Afify SM; Oo AKK; Hassan G; Seno A; Seno M
    Expert Rev Anticancer Ther; 2021 Jun; 21(6):605-619. PubMed ID: 33857392
    [No Abstract]   [Full Text] [Related]  

  • 20. Crosstalk between miRNA and PI3K/AKT/mTOR signaling pathway in cancer.
    Akbarzadeh M; Mihanfar A; Akbarzadeh S; Yousefi B; Majidinia M
    Life Sci; 2021 Nov; 285():119984. PubMed ID: 34592229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.